Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 9/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 6/20 | 1.00 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propranolol SCHEMBL1561135 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Dexpropranolol SCHEMBL29577201 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Levopropranolol SCHEMBL29355940 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Levopropranolol SCHEMBL3956 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL3955 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Dexpropranolol SCHEMBL25255 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL10537386 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL6511347 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL22291223 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL20486000 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| CN-119791834-A | Laser-induced hemangioma embolism interventional therapy device | 吉林大学 | 2025-04-11 | — | — | CN | claimed |
| WO-2024133913-A9 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2025-03-20 | — | — | WO | claimed |
| CN-110869494-B | Without systemic immunosuppression allograft tolerance | 西奈卫生系统公司 | 2025-02-18 | — | — | CN | claimed |
| EP-3712258-B1 | HEMANGIO-COLONY FORMING CELLS | ASTELLAS INST FOR REGENERATIVE MEDICINE (US) | 2025-01-01 | — | — | EP | claimed |
| EP-3849537-B1 | COMBINATION THERAPIES | MIRATI THERAPEUTICS INC (US) | 2024-10-23 | — | — | EP | claimed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | claimed |
| WO-2024133913-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| CN-114098878-B | Hemangioma plugging device, hemangioma plugging treatment device and hemangioma plugging system | 微创神通医疗科技（上海）有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| CN-114098879-A | Hemangioma plugging device, hemangioma plugging treatment device and hemangioma plugging system | 微创神通医疗科技（上海）有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-114098878-A | Hemangioma plugging device, hemangioma plugging treatment device and hemangioma plugging system | 微创神通医疗科技（上海）有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-114098880-A | Hemangioma plugging device, hemangioma plugging treatment device and hemangioma plugging system | 微创神通医疗科技（上海）有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20200197335-A1 | CANCER THERAPEUTIC | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2020-06-25 | — | — | US | claimed |
| CN-110494142-A | Treatment of cancer | GILLIES MCINDOE RES INSTITUTE | 2019-11-22 | — | — | CN | claimed |
| CN-109839444-A | The separation method of naphthol derivative and its application | 武汉科福新药有限责任公司 | 2019-06-04 | — | — | CN | claimed |
| US-9110053-B2 | Dried blood spotting paper device and method | AGILENT TECHNOLOGIES, INC. (US) | 2015-08-18 | — | — | US | claimed |
| US-9078882-B2 | Compositions and methods for preventing cardiac arrhythmia | CORMATRIX CARDIOIOVASCULAR, INC. (US) | 2015-07-14 | — | — | US | claimed |
| US-20150164960-A1 | Compositions and Methods for Preventing Cardiac Arrhythmia | ELUTIA MED LLC | 2015-06-18 | — | — | US | claimed |